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Abstract: The study of pharmacogenomics has, by har-
nessing sequence information from human genomes, the 
potential to lead to novel approaches in drug discovery, 
an individualized application of drug therapy, and new 
insights into disease prevention. For this potential to be 
realized results need to be interpreted to the prescriber 
into a format which dictates an action. This mini review 
briefly describes the history, the regulatory environment, 
opinions towards, and implementation, integration and 
interpretation of pharmacogenomics in the United States 
of America and Europe. The article discusses also how 
interpretation of pharmacogenomics could move forward 
to better implementation in health care.
Keywords: implementation; pharmacogenetics; pharma-
cogenomics; regulatory bodies.
Introduction
Pharmacogenomics
Pharmacogenetics is defined by the International Confer-
ence of Harmonisation (ICH) as ‘The study of variations in 
DNA sequence as related to drug response’ [1]. The terms 
pharmacogenetics and pharmacogenomics are often used 
interchangeably in the literature [2]. Pharmacogenomics 
refers to the whole-genome application of pharmacoge-
netics, which has traditionally been considered to be con-
cerned with single-gene effects [3].
History
In the mid 20th century Vogel coined the term pharmacoge-
netics amidst growing evidence of difference in reactions 
to pharmaceutical drugs [4]. An example is the observed 
adverse reactions to the anti-malarial drug primaquine in 
individuals with a glucose-6-phosphate dehydrogenase 
deficiency [5]. Studies in the late 1960s furthered the field 
by showing that genetically identical individuals, mono-
zygotic twins, had a more similar drug metabolite profile 
than di-zygotic twins [6]. For a time more detailed studies 
were limited by technology. The advent of DNA cloning 
identified in 1988 that variations in cytochrome P450 2D6 
(CYP2D6) were responsible for differences in the metabo-
lism of debrisoquine [7]. Subsequently, several CYP2D6 
polymorphisms have been characterized [8], and the 
protein has been shown to be involved in the metabolism 
of ~25% of all prescribed drugs [9]. CYP2D6 is now thought 
to have over 100 variations, 11 of which have clinical rel-
evance [10]. Towards the end of the 20th century more 
associations of genes encoded in disease pathways, drug 
metabolism, or drug target were discovered [11] leading to 
the current knowledge base we now have.
Current knowledge
In the post-genome era more candidate genes for drug 
response have been identified through micro-arrays 
and genome-wide association studies [12]. Due to the 
volume of information accrued, detailed databases have 
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been created to present the data in a comprehensive and 
searchable fashion [10, 13]. One database, the Pharma-
cogenetic Knowledge Base (PharmGKB), has published 
peer-reviewed guidance on 46 genes that have phar-
macogenomic relevance and are otherwise known as 
pharmacogenes.
Academic, regulatory and industry 
of pharmacogenomics in healthcare
United States of America
The US is showing the lead in the translation of pharma-
cogenomic knowledge into the clinical setting. It is home 
to global pharmacogenomic networks and produces the 
majority of novel research in the field. The Pharmacoge-
netic Global Research Network (PGRN), funded by the 
National Institute of Health in 2000 also initiated the 
PharmGKB database. The Clinical Pharmacogenetics 
Implementation Consortium was set up in 2009 to provide 
peer-reviewed, updated, evidence-based, freely accessi-
ble guidelines for gene/drug pairs [14]. PharmGKB’s data 
are available open source to research institutions who 
subscribe; however, for commercial use it is exclusively 
licensed to an interpretation company based in the US [15].
From a regulatory standpoint the Food and Drug 
Administration has issued their highest recommen-
dation, a boxed warning, to three drug/gene pairs 
(Abacavir – HLA-B 57:01, Carbamazapine – HLA-B 15:02 
and  Clopidogrel – CYP2C19) to advise testing before pre-
scribing. This is clearly laid out in a table of over 100 drug/
biomarker pairs (pharmacogenomic, proteomic, etc.) and 
their various levels of warning [16]. It is estimated that 
7% of all approved medications in the US have actionable 
pharmacogenomics data incorporated in the drug label, 
and many more include relevant information [17].
Also, select insurance companies offer reimburse-
ment for such testing to make it accessible to physicians 
and the public [18]. A number of private companies such 
as YouScript [19] have also started offering pharmacog-
enomic testing to the medical community and to provide 
interpretation.
United Kingdom and Europe
The UK and Europe has a rich history in genetic 
research with many key discoveries taking place there. 
Pharmacogenomic networks are emerging but are less 
established than the PGRN. In 2001 the Committee for 
Medicinal Products for Human Use established a multi-
disciplinary expert group to look at pharmacogenomics 
called the Pharmacogenetic Working Party, which was 
formalized in 2005 and renamed in 2008 to Pharmacog-
enomics Working Party (PGWP) [20]. Also in 2005, the 
Dutch Pharmacogentic Working Group was established 
[21], which has become influential in the area providing 
research to PharmGKB. In 2012 the UK set up the UK Phar-
macogenetics and Stratified Medicines Network, that acts 
as a portal to novel research [22]. The European Society of 
Pharmacogenetics and Theranostics, now known as The 
European Society of Pharmacogenomics and Personalised 
Therapies, was formed after the fifth meeting of The San-
torini Conference on prospective biology, genomics and 
pharmacogenomics in 2010 [23].
In Europe, regulatory recommendations about phar-
macogenomics vary from country to country. Of the 517 
medications approved by the European Medical Agency 
(EMA), which was set up in 1995 with the aim to harmo-
nize member country regulatory efforts, 15% have phar-
macogenomic recommendations in drug labels [24] these 
include Abacavir, Carbamazepine and Clopidogrel as in 
the US (see Section “United States of America”). In 2011, 
Prasad and Breckenridge predicted that the EU regula-
tory bodies will gain momentum in the field [25], and 
subsequently more guidelines have been released [26]. An 
example of this are the guidelines which came into effect 
in August 2012 [27]. These state that any pharmaceutical 
company that wishes to market a medication in Europe 
is required to carry out pharmacogenomic studies on 
the pharmacokinetics of novel small molecules. It is also 
highly recommended that databanks of such data should 
be collected during the drug testing phases. The PGWP is 
tasked to advise companies with such initiatives [28].
Currently, in Europe and the UK, demand for tests is 
low. Four out of 12 genetic laboratories versus 14 out of 15 
histocompatibility and immunogenetics laboratories offer 
pharmacogenomic testing in the UK [29], which is in line 
with Germany where ~36% of laboratories offer testing 
[30]. Only one germline genetic test, the HLA-B*5012, to 
predict Abacavir response is used regularly in the UK [29].
Opinions on pharmacogenomics
Public support has been shown to be essential to translate 
a new technology [31], as are physician’s opinions, which 
are of particular importance as they have been shown to 
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be a vital part of the process for integrating an innovation 
into a healthcare setting [32].
Few studies have been conducted globally into the 
opinions of various different focus groups. Understanding 
opinions towards novel technologies can focus research 
efforts into those areas that need more development to 
reassure adopters and end-users.
Lay persons
In lay-opinion studies in the UK, the public are not at first 
aware of the concept but, when described the technol-
ogy of pharmacogenomics, they are generally optimis-
tic. Members of the public are also not too worried about 
who gives them the information as long as it is commu-
nicated clearly and confidently [33]. In an open dialogue 
study carried out by the Royal Society opinions were again 
optimistic. Concerns that reoccur are privacy of data and 
interpretation of results [34]. In a US study, the public, on 
the whole, were strongly supportive of pharmacogenomic 
testing. Although interest was influenced by a combina-
tion of factors, most notably if an individual had expe-
rienced a previous side effect as a consequence of drug 
treatment [35].
Physicians
Stanek et  al. carried out a study of the medical profes-
sion to determine what distinguished early adopters of 
pharmacogenomic tests in the US [36]. About 12.9% of 
respondents had ordered a test in the 6 months prior to 
the study, 26.4% predicted using a pharmacogenomic 
test in the next 6 months, and the rest would not order 
such a test. The groups were known as early adopters, 
future adopters and non-adopters, respectively. Early 
adopters of pharmacogenomics testing were more likely 
to be those practicing in urban settings, at an interme-
diate stage in their careers (15–29  years since leaving 
medical school), and practicing oncology or a surgical 
specialty.
In a qualitative study of 184 healthcare profession-
als carried out by Dodson and van Riper [37], five themes 
were identified as reoccurring when pharmacogenomics 
is considered. These are negative concerns for the applica-
tion of pharmacogenomics, lack of successful integration 
into standards of care, accessibility of pharmacogenomic 
testing, potential harm and optimism. Versions of these 
themes are also apparent in most opinion-based studies 
globally.
In the UK, to date three studies have been conducted 
to assess physician’s opinions [33, 38, 39]. The Fargher 
et al. study incorporated 17 views of healthcare profession-
als with the lay opinions mentioned above [33]. Hedgecoe 
solely conducted a qualitative study on two physicians 
[38]. Fargher concluded that the opinions of healthcare 
professionals differ from those of the lay persons who are 
more concerned about patient exclusion than informa-
tion delivery. Hedgecoe identified that physicians from 
different specialties highlight different needs from phar-
macogenomic data. Bartlett et al. [39] collected responses 
from 701 participants and showed that the more education 
about pharmacogenomics an individual had, the more 
likely they were to have a positive opinion about testing.
There is a reported lack of pharmacogenomic knowl-
edge in the professional clinical population globally. Calls 
to amend the medical school syllabus to prepare trainee 
doctors for the emergence of personalized medicine have 
appeared in the literature since 2003 [40]. Little has 
changed, with the average syllabus containing no, to little, 
pharmacogenomic information. There has also been a call 
for more Continual Professional Development courses for 
qualified physicians [39]. This is very important, as it will 
create a sympathetic environment for the uptake of the 
technology in line with regulatory guidance.
With new discoveries, alongside better education, 
demand for genetic testing has been predicted to rise sig-
nificantly [41]. In the US especially, there is a rise in direct 
to consumer (DTC) genetic testing companies. However, it 
has been shown that doctors in general are not comforta-
ble and on the whole still dubious about the clinical utility 
of such tests [42]. The rise in demand for DTC genetic 
testing shows that people are more and more becoming 
engaged with their own genome. Europe is very varied in 
its legislation regarding DTC testing [43] with German law 
stating genetic tests can only be reported back to a patient 
by a doctor, while other member states allow a more 
liberal use of such tests.
Implementation, integration and 
interpretation
Various models for implementation of pharmacogenomic 
testing have been proposed in the US [44–46], and reviews 
into how pharmacogenomic information should be inte-
grated into an electronic medical record (EMR) are avail-
able [47]. The RAPID GENE trial is the first study to show 
efficacy of a point-of-care pharmacogenomic test to deter-
mine antiplatelet treatment [48]. The test was an example 
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of how pharmacogenomic information can integrate into 
a physician’s workflow to improve clinical outcomes.
The PREDICT (Pharmacogenomic Resource for 
Enhanced Decisions in Care and Treatment) study at 
Vanderbilt, Tennessee [49] is collecting a participant’s 
184 common polymorphisms across 34 pharmacogenes 
to store in their EMRs and be used in clinical decision 
support (CDS) when needed. As of November 2013 more 
than 10,000 patients have been enrolled, and a prelimi-
nary look at the first 9589 participants showed that 91% 
of the population had at least one clinically actionable 
 genotype for five of the tested pharmacogenes [50].
Most pharmacogenomic implementation projects are 
being carried out at multiple sites across the US [51]. In 
Europe, the Dutch Pharmacogenetic Working Group has 
implemented guidance on 53 drug/gene pairs [52] in phar-
macies across Holland; however, this is not a formal study. 
The first European-wide implementation project called 
Ubiquitous Pharmacogenomics (U-PGx) has recently 
received Horizon 2020 EU grant funding due to start early 
2016 [53].
Interpretation is defined as ‘the action of explaining 
the meaning of something,’ and as the power and validity 
of pharmacogenomic studies increases, geneticists need 
to understand how best we can do this for healthcare pro-
fessionals. In the US, a systematic review has shown that 
from 1990 to 2011, 38 primary studies were conducted to 
assess how all genetic results, not just pharmacogenomics, 
were interpreted by CDS systems [54]. Six of these studies 
looked at pharmacogenomic interpretation, four of which 
were conducted in the US and two in Europe. These initial 
studies provide evidence for applications of pharmacog-
enomics from genetic-guided therapy in HIV treatments to 
novel pharmacogenomics guidelines and proof of concept 
for integration of PharmGKB into clinical decision support.
Integration of pharmacogenomic data into digital 
health solutions has been a major focus for all implemen-
tation projects as it is an efficient way to present relevant 
data in a timely fashion to prescribers [55]. Drug-drug 
interaction clinical decision support in electronic pre-
scribing (UK nomenclature) or Computerized Physician 
Order Entry systems (US nomenclature) can act as a model 
to understand how to best present drug-gene interac-
tions. The positive impact on costs and patient outcomes 
of drug-interaction checkers has been proven in a trial 
environment [56]. However, electronic prescribing needs 
improving as in the clinical environment, 52.6% of alerts 
are overridden due to alert-fatigue [57]. In half of overrides 
it is thought that ignoring alerts could cause significant 
harm. Although there is optimism around these digital 
solutions from users, adoption can be slow [58].
Discussion
In summary, there seem to be large cultural differences 
surrounding the adoption of pharmacogenomics between 
the US and Europe. Europe presents a more conservative 
attitude to translational research than does the US.
Initiatives like Genomics England [59], which is the 
UK’s 100,000 whole genome sequencing project launched 
in 2013, will no doubt push genomic research and transla-
tion forward. However, with a specific focus on rare disease 
and cancer genomics, the nuances of pharmacogenomics 
data interpretation will not be studied. On the other hand 
U-PGx will look at pharmacogenomics interpretation and 
integration; however, results will not be published until 
2020 which seems like a long time to realize the expected 
patient benefits of the technology.
The US has been leading the adoption of pharma-
cogenomics globally and has a more established infra-
structure to support this. The networks across Europe are 
younger; however, support for the industry is growing and 
the relatively connected state health-care systems can 
provide a strong platform for integration. The US also has 
strong leadership from regulators in the field with clear 
guidelines about the efficacy of pharmacogenomic testing. 
These guidelines have been shown to be a good source of 
education for physicians and provoke adoption of technol-
ogies [60]. Clearer guidance from the EMA might encourage 
the adoption of pharmacogenomics into  European clinics.
In both geographical areas, more work is needed to 
understand how to present pharmacogenomic informa-
tion in an actionable format to healthcare professionals. 
Trials have shown that integration of pharmacogenom-
ics is effective in creating better outcomes for patients. 
However, optimism must be controlled, as with drug-drug 
interaction CDS, the real challenge will be how to ensure 
that warnings are implemented. The advent of digital 
technologies to inform the medical profession, combined 
with improved education in pharmacogenomics, holds 
much promise for assessing the best treatment for an indi-
vidual based on their genetic make-up.
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